Patterns of tau pathology identified with 18 F-MK-6240 PET imaging Positron emission tomography (PET) imaging for neurofibrillary tau allows investigation of the in vivo spatiotemporal progression of Alzheimer’s disease (AD) pathology.
New PET imaging tracer helps spot signs of Alzheimer’s disease years before symptoms appear A new positron emission tomography radiotracer has the potential to spot signs of Alzheimer’s disease years before symptoms appear
Case Report: 18F-MK6240 Tau Positron Emission Tomography Pattern Resembling Chronic Traumatic Encephalopathy in a Retired Australian Rules Football Player https://www.frontiersin.org/articles/10.3389/fneur.2020.598980/full
Characterization of MK6240, a tau PET tracer, in autopsy brain tissue from Alzheimer’s disease cases https://link.springer.com/article/10.1007/s00259-020-05035-y
Timing is everything: tau imaging across stages of Alzheimer’s disease https://academic.oup.com/brain/article-abstract/143/9/2634/5908732
Pascoal TA, Therriault J, et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain. 2020; awaa180. https://doi.org/10.1093/brain/awaa180
Betthauser TJ, Koscik RL, Jonaitis EM, et al. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age. Brain. 2020; 143(1):320-335. Doi: 10.1093/brain/awz378. https://academic.oup.com/brain/article/143/1/320/5689568
Koscik RL, Betthauser TJ, Jonaitis EM, et al. Amyloid duration is associated with preclinical cognitive decline and tau PET. Alzheimers Dement (Amst). 2020;12(1):e12007. Doi: 10.1002/dad2.12007. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7085284/
Therriault J, Benedet AL, Pascoal TA, et al. Association of apolipoprotein E ε4 with medial temporal tau independent of amyloid-β. JAMA Neurol. 2020; 77(4):470-479. Doi: 10.1001/jamaneurol.2019.4421. https://pubmed.ncbi.nlm.nih.gov/31860000/
Koole M, Lohith TG, Valentine JL, et al. Preclinical safety evaluation and human dosimetry of [18F]MK-6240, a novel PET tracer for imaging neurofibrillary tangles. Mol Imaging Biol. 2020; 22(1):173-180. Doi: 10.1007/s11307-019-01367-w. https://pubmed.ncbi.nlm.nih.gov/31111397/
Laffon E, Buj S, de Clermont H, Marthan R. Fitting of late dynamic [18F]MK6240 PET scans for in vivo tau quantification. Eur J Nucl Med Mol Imaging. 2020; 47(1):7-8. Doi: 10.1007/s00259-019-04542-x.
Luchsinger JA, Palta P, Rippon B, et al. Sex differences in in vivo Alzheimer’s disease neuropathy in late middle-aged Hispanics. J Alzheimers Dis. 2020; 74(4):1243-1252. Doi: 10.3233/JAD-191183. https://pubmed.ncbi.nlm.nih.gov/32250303/
Lussier FZ, Pascoal TA, Chamoun M, et al. Mild behavioral impairment is associated with β -amyloid but not tau or neurodegeneration in cognitively intact elderly individuals. Alzheimers Dement. 2020; 16(1):192-199. Doi: 10.1002/alz.12007.
McCluskey SP, Plisson C, Rabiner EA, Howes O. Advances in CNS PET: The state-of-the-art for new imaging targets for pathophysiology and drug development. Eur J Nucl Med Mol Imaging. 2020; 47(2):451-489. Doi: 10.1007/s00259-019-04488-0. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6974496/
Therriault J, Benedet AL, Pascoal TA, et al. APOEε4 potentiates the relationship between amyloid-β and tau pathologies. Mol Psychiatry. 2020; [Epub ahead of print]. Doi: 10.101038/s41380-020-0688-6.
Zou J, Tao S, Johnson A, et al. Microglial activation, but not tau pathology, is independently associated with amyloid positivity and memory impairment. Neurobiol Aging. 2020; 85:11-21. Doi: 10.1016/j.neurobiolaging.2019.09.019. https://www.sciencedirect.com/science/article/pii/S0197458019303471?via%3Dihub /
Aguero C, Dhaynaut M, Normandin MD, et al. Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue. Acta Neuropathol Commun. 2019; 7(1):37. Doi: 10.1186/s40478-019-0686-6. https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-019-0686-6
Devanand DP, Andrews H, Kreisl WC, et al. Antiviral therapy: Valacyclovir Treatment of Alzheimer’s Disease (VALAD) Trial: Protocol for a randomized, double-blind, placebo-controlled, treatment trial. BMJ Open. 2020; 10(2):e032112. Doi: 10.1136/bmjopen-2019-032112. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045215/
Murugan NA, Chiotis K, Rodriguez-Vieitez E, Lemoine L, Agren H, Nordberg A. Cross-interaction of tau PET tracers with monoamine oxidase B: Evidence from in silico modelling and in vivo imaging. Eur J Nucl Med Mol Imaging. 2019; 46(6):1369-1382. Doi: 10.1007/s00259-019-04305-8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486902/
Leuzy A, Chiotis K, Lemoine L, et al. Tau PET imaging in neurodegenerative tauopathies – still a challenge. Mol Psychiatry. 2019; 24(8):1112-1134. Doi: 10.1038/s41380-018-0342-8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756230/
Lohith TG, Bennacef I, Vandenberghe R, et al. Brain imaging of Alzheimer dementia patients and elderly controls with 18F-MK-6240, a PET tracer targeting neurofibrillary tangle pathology. J Nucl Med. 2019; 60(1):107-114. Doi: 10.2967/jnumed.118.208215. http://jnm.snmjournals.org/content/60/1/107.long
Betthauser TJ, Cody KA, Zammit MD, et al. In vivo characterization and quantification of neurofibrillary tau PET radioligand MK-6240 in humans from Alzheimer’s disease dementia to young controls. J Nucl Med. 2019; 60(1):93-99. Doi: 10.2967/jnumed.118.209650. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354223/
Guehl NJ, Wooten DW, Yokell DL, et al. Evaluation of pharmacokinetic modeling strategies for in-vivo quantification of tau with the radiotracer [18F]MK6240 in human subjects. Eur J Nucl Med Mol Imaging. 2019; 46(10):2099-2111. Doi: 10.1007/s00259-019-04419-z. https://pubmed.ncbi.nlm.nih.gov/31332496/
Hopewell R, Ross K, Kostikov A, et al. A simplified radiosynthesis of [18F]MK-6240 for tau PET imaging. J Labelled Comp Radiopharm. 2019; 62(2):109-114. Doi: 10.1002/jlcr.3695. https://pubmed.ncbi.nlm.nih.gov/30426529/
Salinas C, Lohith TG, Purohit A, et al. Test-retest characteristic of [18F]MK-6240 quantitative outcomes in cognitively normal adults and subjects with Alzheimer’s disease. J Cereb Blood Flow Metab. 2019; [Epub ahead of print]. Doi: 10.1177/0271678X19887781. https://pubmed.ncbi.nlm.nih.gov/31711342/
Tago T, Toyohara J, Harada R, et al. Characterization of the binding of tau imaging ligands to melanin-containing cells: Putative off-target-binding site. Ann Nucl Med. 2019; 33(6):375-382. Doi: 10.1007/s12149-019-01344-x. https://pubmed.ncbi.nlm.nih.gov/30796626/
Murugan NA, Nordberg A, Agren H. Different positron emission tomography tau tracers bind to multiple binding sites on the tau fibril: Insight from computational modeling. ACS Chem Neurosci. 2018; 9(7):1757-1767. Doi: 10.1021/acschemneuro.8b00093. https://pubmed.ncbi.nlm.nih.gov/29630333
Okamura N, Harada R, Ishiki A, et al. The development and validation of tau PET tracers: Current status and future directions. Clin Transl Imaging. 2018; 6(4):305-316. Doi: 10.1007/s40336-018-0290-y. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096533/
Pascoal TA, Shin M, Kang MS, et al. In vivo quantification of neurofibrillary tangles with [18F]MK-6240. Alzheimers Res Ther. 2018; 10(1):1-14. Doi: 10.1186/s13195-018-0402-y.
Collier TL, Yokell DL, Livni E, et al. cGMP production of the radiopharmaceutical [18F]MK-6240 for PET imaging of human neurofibrillary tangles. J Labelled Comp Radiopharm. 2017; 60(5):263-269. Doi: 10.1002/jlcr.3496. https://pubmed.ncbi.nlm.nih.gov/28185305/
Hostetler ED, Walji AM, Zeng Z, et al. Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles. J Nucl Med. 2016; 57(10):1599-1606. http://jnm.snmjournals.org/content/57/10/1599.long
Walji AM, Hostetler ED, Selnick H, et al. Discovery of 6-(fluoro-(18)F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([(18)F]-MK-6240): A positron emission tomography (PET) imaging agent for quantification of neurofibrillary tangles (NFTs). J Med Chem. 2016; 59(10):4778-89. Doi: 10.1021/acs.jmedchem.6b00166. https://pubmed.ncbi.nlm.nih.gov/27088900/
Collaborators Login